Sertraline in diabetic neuropathy: Preliminary results

Paul J. Goodnick, Isabel Jimenez, Adarsh Kumar

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Previous research has shown that antidepressants have been useful in the treatment of pain, particularly diabetic neuropathy. This study was an initial open investigation into the use of sertraline in diabetic neuropathy. Eight patients with diabetic neuropathy but not depression were treated with increasing doses of sertraline to a maximum of 150 mg/day for 8 weeks. Sertraline treatment led to significant reductions in mean visual analog scale (VAS) ratings, e.g., pain from 71.2 to 23.1 (t = 3.74, p < .01) and paresthesias from 53.8 to 15.0 (t = 4.15, p < .01). Baseline platelet serotonin (5HT) content also correlated significantly with improvement in pain (r = 0.70, p = .05). Plasma sertraline (SRT) correlated with improvement in paresthesias (r = 0.70). Conclusion: This preliminary result indicates the potential application of sertraline to treatment of diabetic neuropathy. A replication is now underway.

Original languageEnglish
Pages (from-to)255-257
Number of pages3
JournalAnnals of Clinical Psychiatry
Volume9
Issue number4
DOIs
StatePublished - Dec 1 1997

Fingerprint

Sertraline
Diabetic Neuropathies
Paresthesia
Pain
Visual Analog Scale
Antidepressive Agents
Serotonin
Therapeutics
Blood Platelets
Depression
Research

Keywords

  • Antidepressant
  • Blood levels
  • Diabetes mellitus
  • Neuropathy
  • Pain
  • Serotonin treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Sertraline in diabetic neuropathy : Preliminary results. / Goodnick, Paul J.; Jimenez, Isabel; Kumar, Adarsh.

In: Annals of Clinical Psychiatry, Vol. 9, No. 4, 01.12.1997, p. 255-257.

Research output: Contribution to journalArticle

Goodnick, Paul J. ; Jimenez, Isabel ; Kumar, Adarsh. / Sertraline in diabetic neuropathy : Preliminary results. In: Annals of Clinical Psychiatry. 1997 ; Vol. 9, No. 4. pp. 255-257.
@article{ba079d9a4c5148a8959a8128981c861c,
title = "Sertraline in diabetic neuropathy: Preliminary results",
abstract = "Previous research has shown that antidepressants have been useful in the treatment of pain, particularly diabetic neuropathy. This study was an initial open investigation into the use of sertraline in diabetic neuropathy. Eight patients with diabetic neuropathy but not depression were treated with increasing doses of sertraline to a maximum of 150 mg/day for 8 weeks. Sertraline treatment led to significant reductions in mean visual analog scale (VAS) ratings, e.g., pain from 71.2 to 23.1 (t = 3.74, p < .01) and paresthesias from 53.8 to 15.0 (t = 4.15, p < .01). Baseline platelet serotonin (5HT) content also correlated significantly with improvement in pain (r = 0.70, p = .05). Plasma sertraline (SRT) correlated with improvement in paresthesias (r = 0.70). Conclusion: This preliminary result indicates the potential application of sertraline to treatment of diabetic neuropathy. A replication is now underway.",
keywords = "Antidepressant, Blood levels, Diabetes mellitus, Neuropathy, Pain, Serotonin treatment",
author = "Goodnick, {Paul J.} and Isabel Jimenez and Adarsh Kumar",
year = "1997",
month = "12",
day = "1",
doi = "10.1023/A:1022360528151",
language = "English",
volume = "9",
pages = "255--257",
journal = "Annals of Clinical Psychiatry",
issn = "1040-1237",
publisher = "Dowden Health Media,Inc",
number = "4",

}

TY - JOUR

T1 - Sertraline in diabetic neuropathy

T2 - Preliminary results

AU - Goodnick, Paul J.

AU - Jimenez, Isabel

AU - Kumar, Adarsh

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Previous research has shown that antidepressants have been useful in the treatment of pain, particularly diabetic neuropathy. This study was an initial open investigation into the use of sertraline in diabetic neuropathy. Eight patients with diabetic neuropathy but not depression were treated with increasing doses of sertraline to a maximum of 150 mg/day for 8 weeks. Sertraline treatment led to significant reductions in mean visual analog scale (VAS) ratings, e.g., pain from 71.2 to 23.1 (t = 3.74, p < .01) and paresthesias from 53.8 to 15.0 (t = 4.15, p < .01). Baseline platelet serotonin (5HT) content also correlated significantly with improvement in pain (r = 0.70, p = .05). Plasma sertraline (SRT) correlated with improvement in paresthesias (r = 0.70). Conclusion: This preliminary result indicates the potential application of sertraline to treatment of diabetic neuropathy. A replication is now underway.

AB - Previous research has shown that antidepressants have been useful in the treatment of pain, particularly diabetic neuropathy. This study was an initial open investigation into the use of sertraline in diabetic neuropathy. Eight patients with diabetic neuropathy but not depression were treated with increasing doses of sertraline to a maximum of 150 mg/day for 8 weeks. Sertraline treatment led to significant reductions in mean visual analog scale (VAS) ratings, e.g., pain from 71.2 to 23.1 (t = 3.74, p < .01) and paresthesias from 53.8 to 15.0 (t = 4.15, p < .01). Baseline platelet serotonin (5HT) content also correlated significantly with improvement in pain (r = 0.70, p = .05). Plasma sertraline (SRT) correlated with improvement in paresthesias (r = 0.70). Conclusion: This preliminary result indicates the potential application of sertraline to treatment of diabetic neuropathy. A replication is now underway.

KW - Antidepressant

KW - Blood levels

KW - Diabetes mellitus

KW - Neuropathy

KW - Pain

KW - Serotonin treatment

UR - http://www.scopus.com/inward/record.url?scp=0031426181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031426181&partnerID=8YFLogxK

U2 - 10.1023/A:1022360528151

DO - 10.1023/A:1022360528151

M3 - Article

C2 - 9511950

AN - SCOPUS:0031426181

VL - 9

SP - 255

EP - 257

JO - Annals of Clinical Psychiatry

JF - Annals of Clinical Psychiatry

SN - 1040-1237

IS - 4

ER -